|
業務類別
|
Biotechnology |
|
業務概覽
|
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED. |
| 公司地址
| 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808 |
| 電話號碼
| +1 800 775-7936 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.yarrowbioscience.com |
| 員工數量
| 4 |
| Mr. Tyler Zeronda |
Chief Financial Officer |
-- |
28/07/2026 |
| Dr. Steven Ryder, M.D. |
Chief Medical Officer |
-- |
28/07/2026 |
| Ms. Rebecca Frey, Pharm.D. |
Chief Executive Officer and Director |
-- |
28/07/2026 |
| Dr. Lori Payton, PhD |
Chief Development Officer |
-- |
28/07/2026 |
| Dr. Rachael Alford, PhD |
Chief Operating Officer |
-- |
28/07/2026 |
|
|
| Mr. Stephen L. Hoerter |
Independent Director |
28/07/2026 |
| Mr. Peter B. Silverman, J.D. |
Independent Director |
28/07/2026 |
| Mr. William R. White, J.D. |
Independent Director |
28/07/2026 |
| Dr. Mona Ashiya, PhD |
Independent Director |
28/07/2026 |
| Dr. Bill Lundberg, M.D. |
Chairman of the Board |
28/07/2026 |
| Ms. Rebecca Frey, Pharm.D. |
Chief Executive Officer and Director |
28/07/2026 |
|
|
|
|
